二肽基肽酶-4抑制剂利格列汀治疗对2型糖尿病患者血清色素上皮细胞衍生因子水平的影响  

Effect of dipeptidyl peptidase-4 inhibitors linagliptin on the expression of serum pigment epithelium-derived factor in type 2 diabetes patients

作　　者：杜姝姗[2] 周婷婷[1] 郭常辉[1] 

机构地区：[1]重庆医科大学附属第二医院内分泌科,400010 [2]成都大学附属医院老年科

出　　处：《中华内分泌代谢杂志》2015年第8期696-699,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：为了解2型糖尿病患者血清色素上皮衍生因子（ PEDF）水平以及予以二肽基肽酶-4抑制剂利格列汀治疗前后PEDF的变化,进一步探讨PEDF与血脂、体重指数、HbA1C等指标相关性。选取39例新诊断2型糖尿病患者和30名健康者进入研究。常规检测2组受试者体重、腰围、体重指数、空腹血糖、HbA1C、血清谷丙转氨酶、谷草转氨酶、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇指标,采用酶联免疫吸附法检测血清PEDF的浓度。2型糖尿病组予口服利格列汀5 mg/d治疗6个月,6个月后再次检测血清PEDF浓度和临床指标,并进行统计学分析。结果显示：（1）治疗前2型糖尿病组血清PEDF浓度与对照组相比浓度相似（P=0.584）,PEDF与低密度脂蛋白胆固醇、腰围呈正相关（P〈0.05或P〈0.01）。（2）经利格列汀治疗6个月后2型糖尿病组血清PEDF水平较治疗前增加,差异具有统计学意义[（3.21±1.91对2.45±1.53）μg/ml, P〈0.01]。2型糖尿病患者血清PEDF水平与对照组相似,与低密度脂蛋白胆固醇、腰围相关,经利格列汀治疗后血清PEDF水平上升,提示利格列汀可能对糖尿病血管并发症有一定保护作用。[Summary] To investigate the difference in serum pigment epithelium-derived factor （ PEDF） among type 2 diabetic patients before and after use of dipeptidyl peptidase-4 inhibitors linagliptin for treatment, and to explore the correlation of serum PEDF with lipids, body mass index, and HbA1C . 39 patients with recently diagnosed type 2 diabetes and 30 healthy individuals were enrolled. Baseline weight, waist circumference, body mass index, fasting plasma glucose, HbA1C , serum glutamic-pyruvic transaminase, glutamic oxaloacetic transaminase, total cholesterol, triglyceride, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol （ LDL-C） , and PEDF measured by enzyme linked immunosorbant assay were determined both in the diabetic and control subject. The treatment group was treated with oral linagliptin 5 mg/d for six month, serum PEDF and clinical parameters were determined in the diabetic group during 6 months of treatment. （ 1 ） PEDF levels were found to be comparable with the controls （ P=0. 584）;LDL-C and waist circumference showed positive correlation with PEDF（P〈0. 05 or P〈0. 01）. （2） PEDF level was significantly increased in patients with type 2 diabetes after linagliptin treatment [（3. 21 ± 1. 91 vs 2. 45 ± 1.53）μg/ml,P〈0.01]. SerumPEDFlevelinpatientswithtype2diabeteswassimilartothatofhealthycontrolswith associated LDL-C and waist circumference. After linagliptin treatment, serum PEDF level was raised, suggesting that it may have certain protective effect for diabetic vascular complications.

关 键 词：糖尿病 2型 色素上皮衍生因子 二肽基肽酶-4抑制剂 

分 类 号：R587.1[医药卫生—内分泌]